Sue Wilson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sue Wilson has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Astrid-Maria Højer
Lundbeck A/S, Clinical and Quantitative Pharmacology, Copenhagen-Valby, Denmark
1 shared publicationDavid J Nutt
Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, London, UK
1 shared publicationHugh Selsick
Royal London Hospital for Integrated Medicine
1 shared publicationJeppe Buchberg
Lundbeck A/S, Clinical and Quantitative Pharmacology, Copenhagen-Valby, Denmark
1 shared publicationJohan Areberg
Lundbeck A/S, Clinical and Quantitative Pharmacology, Copenhagen-Valby, Denmark
1 shared publication
Latest Publications
- 8 June 2018
- Published by Springer Nature
- p. 85-96
Pharmacology of Psychiatric Drugs and Their Effects on Sleep
- 8 June 2018
- Published by Springer Nature
- p. 85-96
Pharmacology of Psychiatric Drugs and Their Effects on Sleep
- 8 June 2018
- Published by Springer Nature
- p. 121-148
The Science and Art of Prescribing for Insomnia
- Open Access
- 6 March 2018
- Published by SAGE Publications in Therapeutic Advances in Psychopharmacology
- Vol. 8 (6) , 171-172
Naming the drugs we use: neuroscience-based nomenclature, a helpful innovation
- 6 March 2018
- Published by SAGE Publications in Therapeutic Advances in Psychopharmacology
- Vol. 8 (6) , 171-172
Open AccessNaming the drugs we use: neuroscience-based nomenclature, a helpful innovation
- Open Access
- 7 August 2015
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 29 (10) , 1085-1091
Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men
We compared the effect of vortioxetine, paroxetine and placebo after three days of dosing on sleep architecture. This was a randomised, double-blind, four-way crossover, placebo-controlled, multiple-dose study in 24 healthy young men. Subjects received 20mg vortioxetine, 40mg vortioxetine, 20mg paroxetine or placebo for three consecutive days in four different periods with at least three weeks between them. Polysomnography and blood sampling for pharmacokinetic analysis were performed on the pre-dose night and nights 1 and 3 of dosing in each period. Plasma concentrations of vortioxetine and paroxetine during the polysomnography measurement were used to estimate SERT occupancies using published relationships in healthy subjects. All three active treatments significantly increased REM onset latency and decreased time spent in REM sleep. In the pharmacokinetic/pharmacodynamics analysis significant relationships were found between REM onset latency and time spent in REM sleep and vortioxetine/paroxetine exposure. The relation between REM suppression parameters and SERT occupancy was significantly different between vortioxetine and paroxetine, despite the same SERT occupancy. This indicates that vortioxetine has a different clinical pharmacological profile from paroxetine, which may explain the differences in adverse effect profile of the two drugs, for instance the lower incidence of nausea, weight gain and sexual dysfunction with vortioxetine.
- 7 August 2015
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 29 (10) , 1085-1091
Open AccessDifferentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men
We compared the effect of vortioxetine, paroxetine and placebo after three days of dosing on sleep architecture. This was a randomised, double-blind, four-way crossover, placebo-controlled, multiple-dose study in 24 healthy young men. Subjects received 20mg vortioxetine, 40mg vortioxetine, 20mg paroxetine or placebo for three consecutive days in four different periods with at least three weeks between them. Polysomnography and blood sampling for pharmacokinetic analysis were performed on the pre-dose night and nights 1 and 3 of dosing in each period. Plasma concentrations of vortioxetine and paroxetine during the polysomnography measurement were used to estimate SERT occupancies using published relationships in healthy subjects. All three active treatments significantly increased REM onset latency and decreased time spent in REM sleep. In the pharmacokinetic/pharmacodynamics analysis significant relationships were found between REM onset latency and time spent in REM sleep and vortioxetine/paroxetine exposure. The relation between REM suppression parameters and SERT occupancy was significantly different between vortioxetine and paroxetine, despite the same SERT occupancy. This indicates that vortioxetine has a different clinical pharmacological profile from paroxetine, which may explain the differences in adverse effect profile of the two drugs, for instance the lower incidence of nausea, weight gain and sexual dysfunction with vortioxetine.